Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: Clinical significance and inhibitory effect of rituximab

Annals of Hematology

Volumn 92, Issue 10, 2013, Pages 1351-1358

  Xu, Zi Zhen ^a   Xia, Zu Guang ^b   Wang, Ai Hua ^a   Wang, Wen Fang ^a   Liu, Zhi Yin ^a   Chen, Li Yun ^a   Li, Jun Min ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Diffuse large B cell lymphoma; PI3K AKT mTOR pathway; Rapamycin; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PROTEIN KINASE B; RAPAMYCIN; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOMA CELL LINE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME; WESTERN BLOTTING;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BLOTTING, WESTERN; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84883868478     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1770-9     Document Type: Article

References (21)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumors: pathology and genetics of tumors of hematopoetic and lymphoid tissues. IARC, Lyon
2. Li JM, Wang L, Shen Y et al (2007) Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Ann Hematol 86:639-645
3. Mey U, Hitz F, Lohri A, Pederiva S, Taverna C, Tzankov A, Meier O, Yeow K, Renner C (2012) Diagnosis and treatment of diffuse large B-cell lymphoma. Swiss Med Wkly 142:0. doi: 10.4414/smw.2012.13511
4. Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511
5. Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 20:1937-1947
6. Uddin S, Hussain AR, Siraj AK et al (2006) Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108:4178-4186
7. Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C, Decker T (2006) Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 134:475-484
8. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655-1657
9. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17:590-603
10. Morgensztern D (2005) McLeod HL.PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16:797-803
11. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282
12. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244
13. Friedberg JW (2011) Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program 2011:498-505
14. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261-1274
15. Fillmore GC, Wang Q, Carey MJ, Kim CH, Elenitoba-Johnson KS, Lim MS (2005) Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas. Leuk Lymphoma 46:1765-1773
16. Hasselblom S, Hansson U, Olsson M et al (2010) High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol 149(4):560-568
17. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758
18. Suzuki E, Umezawa K, Bonavida B (2007) Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 26:6184-6193
19. Ansell SM, Tang H, Kurtin PJ et al (2011) Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 12(4):361-368
20. Fingar DC, Blenis J (2004) Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23:3151-3171
21. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK (2004) AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 279:2737-2746